免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的效果评价

Evaluation of the Effect of Immunotherapy Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer

目的探究免疫治疗联合化疗在中晚期非小细胞肺癌治疗中的效果。方法选取我院2016年10月至2017年12月收治的56例中晚期非小细胞肺癌患者作为研究对象。将所有患者随机均分成实验组、对照组,各28例。给予对照组患者常规化疗治疗,给予实验组患者对照组治疗基础上的免疫治疗。观察、对比两组患者的血清肿瘤标志物情况、细胞免疫指标、体液免疫指标与患者近、远期疗效及不良反应发生情况等。结果治疗后,两组患者血清肿瘤标志物水平均低于治疗前,且实验组患者血清肿瘤标志物水平低于对照组,P<0.05,差异有统计学意义。实验组治疗总有效率96.43%好于对照组89.29%,P<0.05,差异有统计学意义。经1年随访,实验组生存期高于对照组,P<0.05,差异有统计学意义。实验组患者骨髓抑制、恶心呕吐、腹泻发生率均低比对照组低,P<0.05,差异有统计学意义。结论给予中晚期非小细胞肺癌患者免疫治疗联合化疗治疗能够有效延长患者生命,提高患者生存质量,值得临床大力推广及应用。

Objectives To explore the effect of immunotherapy combined with chemotherapy in the treatment of advanced non-small cell lung cancer.Methods Fifty-six patients with advanced non-small cell lung cancer admitted to our hospital from October 2016 to December 2017 were selected as subjects.All patients were randomly divided into experimental group and control group,28 cases each.The control group was given conventional chemotherapy treatment,and the experimental group was given the immunotherapy based on the control group.The serum tumor markers,cellular immune indexes,humoral immune indexes,and the short-term and long-term effects of the patients and the occurrence of adverse reactions were observed and compared between the two groups.Results After treatment,the serum tumor markers in the two groups were lower than before treatment,and the serum tumor markers in the experimental group were lower than the control group,P<0.05,the difference was statistically significant.The total effective rate of the experimental group was 96.43%better than that of the control group(89.29%,P<0.05),and the difference was statistically significant.After 1 year follow-up,the survival time of the experimental group was higher than that of the control group,P<0.05,and the difference was statistically significant.The incidence of myelosuppression,nausea and vomiting and diarrhea in the experimental group were lower than those in the control group,P<0.05,and the difference was statistically significant.Conclusion The combination of immunotherapy and chemotherapy in patients with advanced non-small cell lung cancer can effectively prolong the life of patients and improve the quality of life of patients.It is worthy of clinical promotion and application.